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Abstract Endothelial monocyte-activating polypeptide II
(EMAP II) is a proinflammatory cytokine and a chemoattrac-
tant for leukocytes. The mature cytokine is formed in apoptotic
cells by cleavage of the precursor proEMAP II. Here we show
that caspase-7 is capable of cleaving proEMAP II in vitro. A
proEMAP II mutant, in which the ASTD cleavage site was
changed to the sequence ASTA, was not processed by caspase-7.
The caspase-7-mediated generation and release of mature
EMAP II may provide a mechanism for leukocyte recruitment
to sites of programmed cell death, and thus may link apoptosis to
inflammation.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Endothelial monocyte-activating polypeptide II (EMAP II)
was originally isolated from the supernatant of cultured meth-
ylcholanthrene A (Meth A)-transformed ¢brosarcoma cells
based on its endothelial cell-activating properties [1]. It was
shown to be a proin£ammatory mediator with the ability to
stimulate the chemotactic migration of mononuclear phago-
cytes and polymorphonuclear granulocytes in vitro, and to
induce the expression of tissue factor (the initiator of coagu-
lation) on endothelial cells. In vivo, injection of EMAP II into
the footpad of mice leads to an in£ammatory swelling re-
sponse, which is characterized by an in¢ltration of polymor-
phonuclear granulocytes [1].
The cloning of the EMAP II-cDNA revealed that the ma-
ture 23 kDa form of EMAP II, for which the biological ac-
tivities have been described, is synthesized as a precursor pro-
tein lacking a conventional secretion signal peptide [2]. This
precursor (proEMAP II) was recently found to be identical to
the p43 subunit of the mammalian tRNA multi-synthetase
complex [3]. It is assumed that proEMAP II/p43 functions
as a cofactor for the tRNA synthetases in the complex by
stabilizing the interaction between these enzymes and the cor-
responding tRNAs [3,4].
We have recently demonstrated [5] that proEMAP II/p43 is
cleaved to the mature, chemotactic EMAP II and released
only by apoptotic cells, but not by healthy or necrotic cells.
In this respect, proEMAP II resembles the substrates which
are hydrolyzed by members of the caspase family of proteases
[6]. Caspases are activated in apoptotic cells and subsequently
cleave diverse target proteins (like poly(ADP-ribose) polymer-
ase (PARP) or protein kinase CN) speci¢cally after aspartate
residues. The caspase-mediated cleavage of regulatory, meta-
bolic and structural proteins contributes to the breakdown of
cellular functions which ¢nally results in cell death.
The exact position of the cleavage site within the proEMAP
II sequence (after the amino acid motif ASTD at position 144)
was determined by N-terminal sequencing of the mature mur-
ine protein isolated from cellular supernatants [2]. We have
shown recently [5] that the cleavage of proEMAP II in cul-
tured cells can be inhibited by the addition of benzyloxycar-
bonyl-ASTD-£uoromethylketone (Z-ASTD-FMK), a tetra-
peptide-based inhibitor mimicking the cleavage site of
proEMAP II. The caspase-3 inhibitor benzyloxycarbonyl-
DEVD-chloromethylketone (Z-DEVD-CMK) also inhibited
the cleavage. In this study, we demonstrate that in vitro trans-
lated proEMAP II is cleaved by recombinant caspase-7 and,
to a lesser extent, by caspase-3, but not by other known cas-
pases. A proEMAP II mutant in which the ASTD cleavage
site was changed to the sequence ASTA was not cleaved by
caspase-7. Based on these results, we propose that caspase-7 is
the EMAP II-cleaving protease in apoptotic cells.
2. Materials and methods
All reagents were purchased from Sigma (Deisenhofen, Germany)
unless otherwise indicated. Z-ASTD-FMK, Z-DEVD-CMK, acetyl-
ASTD-aminomethylcoumarin (ASTD-AMC) and acetyl-DEVD-ami-
nomethylcoumarin (DEVD-AMC) were obtained from Bachem (Hei-
delberg, Germany).
2.1. Plasmids
For expression of proEMAP II, the full-length cDNA of mouse
proEMAP II [2] cloned in pBluescript II SK (Stratagene, La Jolla,
CA, USA) was used (insert size: 960 bp). From this, a plasmid for the
expression of proEMAP II with a mutated cleavage site (ASTA-pro-
EMAP II) was generated with the ‘QuikChange site directed muta-
genesis kit’ (Stratagene) using the mutagenic sense primer 5P-
GCAGTCGGCAGCAGCAAGTACTGCCTCCAAGCCTATCG-3P.
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2.2. In vitro translation of proEMAP II
Coupled transcription/translation reactions were performed using
the TNT coupled rabbit reticulocyte lysate system (Promega Biotech,
Madison, WI, USA) according to the manufacturers instructions.
Murine wild-type proEMAP II and ASTA-proEMAP II were ex-
pressed using the plasmids pBluescript II SK/proEMAP II or pBlue-
script II SK/ASTA-proEMAP II as templates for T7 RNA polymer-
ase.
2.3. In vitro cleavage assays
Murine caspases were expressed in Escherichia coli and puri¢ed to
homogeneity [7]. During bacterial expression, the caspases are auto-
processed into p20 and p10 subunits. The p20 subunit was used to
determine the amount of active enzyme as described by Van de Craen
et al. [7]. The caspases were incubated with 2 Wl in vitro translated,
35S-methionine labeled proEMAP II for 1.5 h at 37‡C in a total
volume of 25 Wl in CFS bu¡er [8]. The samples were then analyzed
by SDS/PAGE followed by autoradiography. Cleavage of PARP was
determined by incubating 100 ng of puri¢ed bovine PARP (Biomol,
Hamburg, Germany) with recombinant caspases in a total volume of
25 Wl in CFS bu¡er for 1.5 h at 37‡C. The samples were analyzed by
Western blot.
For £uorometric cleavage assays, recombinant caspases were incu-
bated with 50 WM of the substrates ASTD-AMC or DEVD-AMC in a
total volume of 25 Wl in CFS bu¡er for 1 h at 37‡C. Then the £uo-
rescence of the samples was measured (excitation wavelength: 360 nm,
emission wavelength: 460 nm).
2.4. SDS polyacrylamide gel electrophoresis (SDS/PAGE) and
autoradiography
SDS/PAGE was performed as described recently [5]. For the detec-
tion of EMAP II, the denatured samples were separated on 15% gels.
For the detection of PARP, 8% gels were used. After electrophoresis,
the polyacrylamide gels were ¢xed in 30% methanol/7% acetic acid/
0.5% methionine, then incubated in Amplify solution (Amersham,
Braunschweig, Germany) for 20 min and dried. Finally the gels
were exposed to X-OMAT AR ¢lm (Kodak) at 380‡C. Alternatively,
the dried gel was analyzed using a phosphorimager (Molecular Dy-
namics, Sunnyvale, CA, USA).
2.5. Western blot analysis
Following the transfer of proteins from SDS/PAGE gels onto nitro-
cellulose (Schleicher and Schu«ll, Dassel, Germany) and blocking with
PBS/5% non-fat dry milk, the membranes were incubated with the
monoclonal PARP-speci¢c antibody C2.10 (Enzyme Systems Prod-
ucts, Livermore, CA, USA; diluted 1:10 000) for 2 h at room temper-
ature. The membranes were then washed and incubated with perox-
idase-coupled goat anti-mouse IgG (Jackson, West Grove, USA;
diluted 1:3500) for 1 h. After washing, the membranes were developed
using the ECL-kit (Amersham).
3. Results
3.1. Cleavage of proEMAP II by caspase-7 and caspase-3
In order to investigate whether proEMAP II serves as a
substrate for any of the known caspases, we employed a cleav-
age assay in which in vitro translated proEMAP II was in-
cubated with recombinant caspases. In vitro translation of the
proEMAP II cDNA generated two translation products (Fig.
1, control). The apparent molecular mass of the upper band
(43 kDa) corresponds to the size of the natural proEMAP II,
while the lower band might be due to the usage of an internal
ribosome entry site. We found that caspase-1, -2, -6, -8 and
-11 at concentrations of 500 nM (referring to the p20 subunit
of the active caspases) were not able to process in vitro trans-
lated proEMAP II (Fig. 1). In contrast, complete cleavage of
the substrate was seen within 90 min with 500 nM caspase-7,
and partial processing was found after incubation with cas-
pase-3 (Fig. 1). The apparent molecular mass of the cleavage
product (23 kDa) corresponds to the size of mature EMAP II
as reported by Kao et al. [1]. After longer exposure of the
¢lm, an additional faint band of 20 kDa could be observed
(data not shown). This band corresponds to the N-terminal
cleavage fragment of proEMAP II, which contains only two
methionine residues.
3.2. ProEMAP II is cleaved more e⁄ciently by caspase-7 than
by caspase-3
Having demonstrated that caspase-3 and -7 are able to
cleave proEMAP II, we wanted to compare the a⁄nities of
both enzymes for this substrate. Therefore, we incubated in
vitro translated proEMAP II with increasing concentrations
of caspase-3 (Fig. 2A) or caspase-7 (Fig. 2B). Our results
demonstrate that proEMAP II is cleaved more e⁄ciently by
caspase-7 than by caspase-3. About 50% of the substrate was
processed when caspase-7 concentrations between 30 and 60
nM were used (Fig. 2B). In contrast, approximately 10-fold
higher concentrations of caspase-3 were needed to obtain
comparable amounts of the cleaved product (Fig. 2A; Fig.
1). We further tested the cleavage of PARP by increasing
concentrations of caspase-3 and -7. As PARP is reported to
be cleaved by both enzymes with almost identical a⁄nities [9],
these proteolytic reactions served as a control for the activities
of the two recombinant caspases. Western blot analysis dem-
onstrated that caspase-3 (Fig. 2C) and caspase-7 (Fig. 2D)
were equally active with regard to the cleavage of PARP,
indicating that the di¡erential cleavage of proEMAP II is
not due to di¡erent activities of the recombinant caspases.
3.3. Cleavage of proEMAP II by caspase-7 is time-dependent
and can be inhibited by Z-ASTD-FMK
To obtain further information about the time course of the
cleavage, in vitro translated proEMAP II was incubated with
125 nM caspase-7 for di¡ering lengths of time. Already after
5 min of co-incubation, the mature 23 kDa EMAP II could be
detected (Fig. 3A). After 90 min, almost complete cleavage of
the substrate was obtained. We then examined whether the
proteolytic reaction can be inhibited using the compounds
Z-ASTD-FMK (a competitive inhibitor mimicking the
EMAP II cleavage site) and Z-DEVD-CMK (an inhibitor
for caspase-3 and -7), which have been shown to inhibit the
Fig. 1. Cleavage of proEMAP II by recombinant caspases in vitro.
In vitro translated proEMAP II labeled with 35S-methionine was in-
cubated with recombinant caspases (at concentrations of 500 nM)
for 90 min at 37‡C. The samples were then subjected to SDS/PAGE
and analyzed using a phosphorimager or, in the case of caspase-2,
by autoradiography. Indicated are the positions of proEMAP II
(upper arrow) and the cleaved form (lower arrow).
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cleavage of the EMAP II precursor in cultured apoptotic cells
[5]. Indeed, the processing of in vitro translated proEMAP II
by caspase-7 was completely inhibited by 10 WM Z-ASTD-
FMK and also by 10 WM Z-DEVD-CMK (Fig. 3B).
3.4. ASTA-proEMAP II is not processed by caspase-7
The ASTD cleavage site of proEMAP II does not display a
close similarity to described target sequences for caspase-7,
such as the motif DEVD [10]. Therefore, we investigated
whether the cleavage of proEMAP II by caspase-7 occurs at
the ASTD motif or at an alternative aspartate residue. We
generated a site-speci¢c proEMAP II mutant, in which the
aspartate of the ASTD sequence was replaced by an alanine.
After in vitro translation, the resulting ASTA-proEMAP II
was incubated with recombinant caspases. Indeed, this mutant
protein was neither processed by caspase-7 nor by caspase-3
(Fig. 4A), demonstrating that the ASTD site is essential for
the substrate recognition. To con¢rm that caspase-7 and cas-
pase-3 are able to recognize the ASTD motif, we performed
£uorometric cleavage assays using the tetrapeptide-based sub-
strate ASTD-AMC (Fig. 4B). This substrate was cleaved by
both caspases with almost identical a⁄nities. However,
DEVD-AMC (which is the prototype substrate for caspase-
7) was more e⁄ciently processed by caspase-7 than ASTD-
AMC (Fig. 4B).
4. Discussion
Several lines of evidence suggest that a caspase might be
responsible for the processing of proEMAP II: Firstly, the
cleavage takes place after an aspartate residue. Secondly, the
cleaved, mature EMAP II is only generated by apoptotic, but
not by healthy or necrotic cells [5]. It is known that most
caspases are activated during apoptotic, but not necrotic cell
death [11,12]. Finally, cleavage of proEMAP II in apoptotic
cells can be inhibited by Z-ASTD-FMK and by the caspase-3
inhibitor Z-DEVD-CMK [5], suggesting that the EMAP II-
cleaving enzyme shows structural similarities to caspases.
In an in vitro assay, we could show that only caspase-7 and
(to a lesser degree) caspase-3, but not other caspases, are able
to cleave proEMAP II to a fragment corresponding to the size
of mature EMAP II [1,5]. Surprisingly, caspase-2, which is
reported to have a similar substrate speci¢city as caspase-3
and -7 [10], did not cleave proEMAP II. Several reports claim
that caspase-3 and -7 display almost indistinguishable cleav-
age activities and substrate speci¢cities [9,10]. In contrast, we
found clear di¡erences between both enzymes with regard to
their ability to cleave proEMAP II (although PARP was pro-
cessed by both caspases with very similar a⁄nities). In sup-
port of this ¢nding is a report showing that kinectin (a protein
involved in microtubule-based vesicle transport) is also pro-
cessed by caspase-7 and not by caspase-3 [13]. In contrast to
the proEMAP II protein, a small substrate comprising only
the ASTD motif (ASTD-AMC) was cleaved by caspase-3 and
-7 with comparable a⁄nities. This indicates that the di¡erent
cleavage activities of both enzymes towards proEMAP II are
not based on di¡erences in cleavage site recognition between
the two caspases, but are rather due to steric factors.
Fig. 2. Comparison of proEMAP II cleavage by caspase-7 and caspase-3. In vitro translated proEMAP II was incubated with increasing con-
centrations of caspase-3 (A) or caspase-7 (B) for 1.5 h at 37‡C. Indicated are the concentrations of the p20 caspase subunit. Control incuba-
tions were carried out in the absence of caspases. The samples were analyzed by SDS/PAGE followed by autoradiography. Cleavage of PARP
(4 Wg/ml) by increasing concentrations of caspase-3 (C) and caspase-7 (D) was determined by Western blot analysis.
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According to a study in which the substrate speci¢cities of
several caspases were de¢ned [10], we did not expect the
ASTD site of proEMAP II to be recognized by caspase-3 or
caspase-7, as both enzymes reportedly display a strong pref-
erence for an aspartate residue at the P4 position of the cleav-
age site with DEVD being the optimal recognition motif. As
we have shown that proEMAP II is e⁄ciently processed by
caspase-7 in vitro, it was important to identify the site at
which this cleavage occurs. The sequence of proEMAP II
contains several potential recognition sites for caspases. Of
special interest was an EEVD motif (at amino acid position
178 of proEMAP II), which closely resembles the optimal
target sequence DEVD. However, a proEMAP II mutant in
which the ASTD motif (at position 144) was changed to
ASTA could not be cleaved by caspase-7 or caspase-3, dem-
onstrating that the ASTD site is essential for proEMAP II
recognition by both caspases. Furthermore, using the sub-
strate ASTD-AMC, we could con¢rm that both enzymes are
in principle capable of recognizing the ASTD motif. This
¢nding is further supported by a report [14] showing that
caspase-3 can convert pro-interleukin-16 into mature interleu-
kin-16 by cleaving at a very similar site (SSTD).
In conclusion, caspase-7 and (to a lesser extent) caspase-3
process proEMAP II at the ASTD motif, and thus generate a
cleavage product with an identical N-terminus as the origi-
nally described mature EMAP II [2]. The inability of cas-
pase-7 to cleave the EEVD motif might be due to the three-
dimensional structure of proEMAP II. Our suggestion that
caspase-7 is the EMAP II-cleaving enzyme under physiologi-
cal conditions is further supported by the observation that
both the processing of proEMAP II by caspase-7 in vitro
and the generation of mature EMAP II in apoptotic cells
Fig. 3. A: Time course of proEMAP II cleavage by caspase-7. 35S-
labeled proEMAP II was incubated with 125 nM recombinant cas-
pase-7 at 37‡C for the times indicated. The samples were then ana-
lyzed by SDS/PAGE and autoradiography. B: Inhibition of proE-
MAP II cleavage in vitro by Z-ASTD-FMK. In vitro translated
proEMAP II was incubated with 125 nM recombinant caspase-7 for
1.5 h at 37‡C in the absence or presence of 10 WM Z-ASTD-FMK
or Z-DEVD-CMK. The samples were then subjected to SDS/PAGE
followed by autoradiography. The control lane shows in vitro trans-
lated proEMAP II incubated in the absence of caspases.
Fig. 4. A: ASTA-proEMAP II is not processed by caspase-7. In vi-
tro translated proEMAP II or ASTA-proEMAP II was incubated
without caspases (control) or with recombinant caspase-7 or cas-
pase-3 (at concentrations of 125 nM p20) for 1.5 h at 37‡C. The
samples were then analyzed by SDS/PAGE and autoradiography.
B: Cleavage of ASTD-AMC by caspase-7 and caspase-3. 50 WM
ASTD-AMC or DEVD-AMC was incubated with the indicated con-
centrations of caspase-7 or caspase-3 for 1 h at 37‡C. Fluorescence
was measured, and the concentration of the released AMC group
was determined using an AMC standard curve. E : cleavage of
ASTD-AMC by caspase-7; a : cleavage of ASTD-AMC by caspase-
3; O : DEVD-AMC cleavage by caspase-7.
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can be inhibited by the same compounds (Z-ASTD-FMK or
Z-DEVD-CMK).
We have demonstrated recently [5] that proEMAP II is
processed at a late time point during apoptotic cell death,
while the activation of caspase-7 is known to be an early event
in apoptotic cells [15]. In accordance with these ¢ndings, we
observed that the appearance of active caspase-7 in lysates of
apoptotic Meth A ¢brosarcoma cells precedes the appearance
of mature EMAP II by 4^6 h (data not shown). One possible
explanation for this discrepancy is that in healthy cells, p43/
proEMAP II is enclosed in the tRNA multi-synthetase com-
plex and could thereby be protected from proteolysis. During
progression of the apoptosis program, the complex may dis-
assemble or change its conformation and proEMAP II may
then become accessible for caspase-7. Secondly, following its
activation, caspase-7 has been reported to be located in micro-
somes and mitochondria [16,17], where it cannot interact with
the cytosolic proEMAP II. Only later during apoptosis, when
the membranes of these organelles become permeable, the
active enzyme might come into contact with its substrate pro-
EMAP II. In favor of this hypothesis is the ¢nding that the
protein PARP, although cleaved equally by both caspase-3
and -7 in vitro, is predominantly cleaved by caspase-3 in
vivo [18]. Therefore, it is likely that during early apoptosis,
active caspase-7 is enclosed in subcellular organelles and can-
not interact with cytoplasmic or nuclear substrates.
The ¢nding that mature EMAP II is generated late during
apoptosis has several implications for the potential role of
EMAP II. In most in vivo settings, apoptotic cells are phago-
cytosed at an early stage, before the plasma membrane rup-
tures [19]. This rapid clearance avoids the leakage of proin-
£ammatory factors from the dying cells. In such cases, where
only a few cells undergo apoptosis, the dying cells are likely to
be cleared before proEMAP II is processed. However, a re-
cent report [20] has demonstrated that severe apoptosis can
induce in£ammatory events. At sites of massive apoptosis, the
neighboring cells may fail to phagocytose all of the dying
cells. Subsequently, some cells reach a late stage of apoptosis.
We propose that the generation of mature EMAP II in vivo is
particularly important at sites where extensive cell death oc-
curs. The late apoptotic cells found in such areas could release
mature EMAP II, which then attracts leukocytes. The re-
cruited mononuclear phagocytes may contribute to the clear-
ance of dying cells, while the polymorphonuclear granulocytes
could induce an in£ammatory response. Therefore, we suggest
that EMAP II functions as a link between severe apoptosis
and in£ammation.
In conclusion, the processing of EMAP II by caspase-7 can
contribute to the events of apoptosis by two distinct mecha-
nisms. Firstly, the generated mature EMAP II can recruit
leukocytes to the site of apoptotic cell death. Secondly, after
cleavage, proEMAP II/p43 should no longer function as a
tRNA synthetase cofactor, and this may contribute to the
breakdown of cellular protein synthesis.
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